Grundläggande statistik
| CIK | 1552795 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Benitec Biopharma Ltd
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| April 27, 2020 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39267 Benitec Biopharma Limited* (Exact name of registrant as spe |
|
| April 15, 2020 |
Benitec Biopharma Appoints Edward Smith to the Board of Directors Exhibit 99.1 Benitec Biopharma Appoints Edward Smith to the Board of Directors Hayward, CA - April 14, 2020 - Benitec Biopharma, Inc., a successor entity to Benitec Biopharma Limited (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today announced the appointment of Edward Smith to the Board of Directors. Edward brings more than 20 ye |
|
| April 15, 2020 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William Street, Melbourne, VIC 3000, AUSTRALIA (Address of registrant’s p |
|
| April 15, 2020 |
BNTC / Benitec Biopharma Ltd POS AM - - POS AM POS AM As filed with the Securities and Exchange Commission on April 15, 2020 Registration No. |
|
| April 15, 2020 |
BNTC / Benitec Biopharma Ltd POS AM - - POS AM POS AM As filed with the Securities and Exchange Commission on April 15, 2020 Registration No. |
|
| April 15, 2020 |
BNTC / Benitec Biopharma Ltd S-8 POS - - S-8 POS Registration No. 333-209398 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BENITEC BIOPHARMA LIMITED (Exact Name of Registrant as Specified in Its Charter) Australia Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification |
|
| April 14, 2020 |
BNTC / Benitec Biopharma Ltd 25 - - 25 25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37518 Benitec Biopharma Limited The Nasdaq Capital Market (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) |
|
| April 3, 2020 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William St, Melbourne, VIC, 3000 Australia Indicate by check mark whether |
|
| April 3, 2020 |
EX-99 2 bntc-ex996.htm EX-99 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma Limited Announces Voluntary Delisting of American Depositary Shares and Warrants from the NASDAQ Capital Market in Connection with Its Redomiciliation to the United States MELBOURNE, April 3, 2020 (GLOBE NEWSWIRE) – Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (“Benitec” or the “Company”) announces that for |
|
| March 31, 2020 |
EX-99 2 bntc-ex996.htm EX-99 ASX/NASDAQ ANNOUNCEMENT Position on FIRB approval Melbourne – 31 March 2020 – Benitec Biopharma Limited (Benitec or the Company) (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) refers to its trading halt request dated 30 March 2020. The Foreign Investment Review Board (FIRB) has now confirmed that the new changes to the foreign investment regime do not apply to agreements entered |
|
| March 31, 2020 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William St, Melbourne, VIC, 3000 Australia Indicate by check mark whether |
|
| March 30, 2020 |
ASX/NASDAQ ANNOUNCEMENT Court approves re-domiciliation scheme Melbourne – 30 March 2020 – Benitec Biopharma Limited (Benitec or the Company) (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) is pleased to announce that the Supreme Court of Queensland (Court) has today approved the scheme of arrangement to re-domicile the Benitec group from Australia to the United States of America. |
|
| March 30, 2020 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William St, Melbourne, VIC, 3000 Australia Indicate by check mark whether |
|
| March 30, 2020 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William St, Melbourne, VIC, 3000 Australia Indicate by check mark whether |
|
| March 30, 2020 |
Appendix 3Y Change of Director’s Interest Notice EX-99 2 bntc-ex996.htm EX-99 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Benitec Biopharma Limited ABN 64 068 |
|
| March 26, 2020 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William St, Melbourne, VIC, 3000 Australia Indicate by check mark whether |
|
| March 26, 2020 |
EX-99.2 3 bntc-ex9927.htm EX-99.2 Benitec Biopharma Limited Scheme Meeting Thursday, 26 March 2020 Voting Results The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth). Resolution details Instructions given to validly appointed proxies (as at proxy close) Number of votes cast on the poll Resolution Result Resolution For Against Proxy's Discret |
|
| March 26, 2020 |
EX-99.1 2 bntc-ex9916.htm EX-99.1 26 March 2020 Results of Scheme Meeting In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), Benitec Biopharma Limited (“Benitec” or the “Company”) (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) advises that the results of the Company’s Scheme Meeting are set out in the attached proxy summary. The resolution was passed by poll. - En |
|
| March 18, 2020 |
Benitec Biopharma Limited Independent Expert’s Report EX-99.5 6 bntc-ex9959.htm EX-99.5 Exhibit 99.5 Exhibit 99.5 McGrathNicol Transaction Advisory ABN 83 160 621 054 Level 12,20 Martine Place Sydney NSW 2000, Australia GPO Box 9986 Sydney NSW 2000, Australia 16 January 2020 T+61 2 9338 2600 The Directors F+61 2 9338 2699 Benitec Biopharma Limited mvgrathnicol.com Level 14, 114 William Street Melbourne VIC 3000 1 Executive summary Independent Expert’ |
|
| March 18, 2020 |
EX-99.1 2 bntc-ex99112.htm EX-99.1 Exhibit 99.1 THIS IS AN IMPORTANT DOCUMENT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF YOU ARE IN ANY DOUBT ABOUT HOW TO DEAL WITH THIS DOCUMENT, YOU SHOULD CONTACT YOUR BROKER OR FINANCIAL, TAXATION, LEGAL OR OTHER PROFESSIONAL ADVISER IMMEDIATELY. Benitec Biopharma Limited Scheme Booklet This Scheme Booklet is for the proposed scheme of arrangement between Benite |
|
| March 18, 2020 |
Exhibit 99.6 ASX/NASDAQ ANNOUNCEMENT COVID-19 information relating to Scheme Meeting Melbourne – 17 March 2020 – Benitec Biopharma Limited (Benitec or the Company) (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) announced on 7 February 2020 that a meeting of Benitec’s ordinary shareholders (Benitec Shareholders) will be convened to consider a scheme of arrangement under which Benitec Biopharma Inc., a newly |
|
| March 18, 2020 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William Street, Melbourne, VIC 3000, AUSTRALIA (Address of registrant’s p |
|
| March 18, 2020 |
EX-99.4 5 bntc-ex99410.htm EX-99.4 Exhibit 99.4 Execution version Amended and Restated Scheme Implementation Agreement Benitec Biopharma Limited ACN 068 943 662 Benitec Biopharma Inc. Jones Day Riverside Centre, Level 31 123 Eagle Street Brisbane QLD 4000, Australia Tel: 61 7 3085 7000 Fax: 61 7 3085 7099 www.jonesday.com Contents 1. Definitions and interpretation 1 1.1 Definitions 1 1.2 Interpret |
|
| March 18, 2020 |
EX-99.2 3 bntc-ex9928.htm EX-99.2 Exhibit 99.2 Scheme of Arrangement Benitec Biopharma Limited The holders of fully paid ordinary shares in Benitec Biopharma Limited as at the Record Date Jones Day Riverside Centre, Level 31 123 Eagle Street Brisbane QLD 4000, Australia Tel: 61 7 3085 7000 Fax: 61 7 3085 7099 www.jonesday.com Contents 1. Definitions and interpretation 1 1.1 In this document, unles |
|
| March 18, 2020 |
EX-99.3 4 bntc-ex99311.htm EX-99.3 Exhibit 99.3 Deed Poll By Benitec Biopharma Inc. in favour of each Scheme Participant Jones Day Riverside Centre, Level 31 123 Eagle Street Brisbane QLD 4000, Australia Tel: 61 7 3085 7000 Fax: 61 7 3085 7099 www.jonesday.com Contents 1. Operative Provisions 1 1.1 Definitions and interpretation Definitions 1 1.2 Interpretation 1 2. Nature of Deed Poll 2 3. Condit |
|
| February 26, 2020 |
EX-99.1 2 bntc-ex9916.htm EX-99.1 Exhibit 99.1 BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 Appendix 4D Results for Announcement to the Market for the half-year ended December 31, 2019 The following information is provided under listing rule 4.2A 1. Reporting period The financial information contained in this report is for the half-year ended December 31, 2019. Comparative amounts for the Consolid |
|
| February 26, 2020 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K 6-K 1 bntc-6k20200228.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William Street, Melbourne, VIC, 3000, Au |
|
| February 7, 2020 |
EX-99.1 2 bntc-ex9916.htm BENITEC ANNOUNCES RE-DOMICILIATION TO THE UNITED STATES ASX/NASDAQ ANNOUNCEMENT Court orders convening of Scheme Meeting Melbourne – 7 February 2020 – Benitec Biopharma Limited (Benitec or the Company) (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) announces that the Supreme Court of Queensland (Court) today ordered that a meeting of Benitec’s ordinary shareholders (Benitec Shareho |
|
| February 7, 2020 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K ANNOUNCEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2020 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William Street, Melbourne, VIC 3000, AUSTRALIA (Address of registrant’ |
|
| January 31, 2020 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K 6-K 1 bntc-6k20191231.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2020 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) 14/114 William Street, Melbourne, VIC, 3000, Australia |
|
| January 31, 2020 |
Appendix 4C: Quarterly Cash Flow Report EX-99.1 2 bntc-ex9916.htm EX-99.1 Exhibit 99.1 Appendix 4C: Quarterly Cash Flow Report Highlights: • Cash reserves of approximately A$19.6 million • Finalized design of BB-301 tissue transduction study in large animals • Preclinical BB-301 dosing to begin March 2020; final data expected later this year Melbourne – January 31, 2020 – Benitec Biopharma (ASX: BLT, NASDAQ: BNTC) ("Benitec" or the "Com |
|
| January 31, 2020 |
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B EX-99.2 3 bntc-ex9927.htm EX-99.2 Exhibit 99.2 Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Name of entity BENITEC BIOPHARMA LIMITED ABN Quarter ended (“current quarter”) 64 068 943 662 31 December 2019 Consolidated statement of cash flows Current quarter $A’000 Year to date (6 months) $A’000 |
|
| January 23, 2020 |
BNTC / Benitec Biopharma Ltd / Empery Asset Management, LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Benitec Biopharma Limited (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 082053406** (CUSIP Number) December 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whi |
|
| December 17, 2019 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-235412 Prospectus Benitec Biopharma Limited 64,257,200 Ordinary Shares represented by 321,286 American Depositary Shares This prospectus relates to the offer and sale from time to time by the selling shareholders identified in this prospectus of up to 64,257,200 ordinary shares of Benitec Biopharma Limited, represented b |
|
| December 12, 2019 |
BNTC / Benitec Biopharma Ltd CORRESP - - CORRESP Benitec Biopharma Limited Level 14, 114 William Street Melbourne, VIC 3000 Australia December 12, 2019 via EDGAR U. |
|
| December 9, 2019 |
BNTC / Benitec Biopharma Ltd F-1 - - F-1 F-1 Table of Contents As filed with the Securities and Exchange Commission on December 9, 2019. |
|
| December 6, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William Street, Melbourne, VIC 3000, AUSTRALIA (Address of registrant’ |
|
| December 6, 2019 |
Appendix 3B New issue announcement, application for quotation of additional securities and agreement EX-99.1 2 bntc-ex9916.htm BENITEC ANNOUNCES RE-DOMICILIATION TO THE UNITED STATES Exhibit 99.1 Appendix 3B New issue announcement Rule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New issue announcement, application for quotation of additional securities and agreement Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’ |
|
| December 6, 2019 |
This appendix is not available as an online form Exhibit 1.1 Please fill in and submit as a PDF announcement +Rule 2.7 Appendix 2A Application for quotation of +securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. If you are an entity incorporated outside Australia and y |
|
| December 6, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William St, Melbourne, VIC, 3000 Australia Indicate by check mark whet |
|
| December 6, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William Street, Melbourne, VIC 3000, AUSTRALIA (Address of registrant’ |
|
| December 6, 2019 |
Exhibit 1.1 29 November 2019 2019 Annual General Meeting – Results of Meeting In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), Benitec Biopharma Limited (“Benitec” or the “Company”) (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) advises that the results of the Company’s 2019 Annual General Meeting are set out in the attached proxy summary. Each resolution was pa |
|
| November 27, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, 114 William Street, Melbourne, VIC 3000, AUSTRALIA (Address of registrant’ |
|
| November 27, 2019 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Re-domiciliation to the United States Melbourne – 27 November 2019 - Benitec Biopharma Limited ("Benitec" or the "Company") (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) is pleased to announce its intention to re-domicile from Australia to the United States of America. To implement the re-domiciliation, Benitec has entered into a Scheme Implementation Agreement dated 27 |
|
| November 19, 2019 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec changes ADS ratio Melbourne – 18 November 2019 - Benitec Biopharma Limited ("Benitec" or the "Company") (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) has its ordinary shares ("Shares") listed on the ASX and American Depositary Shares ("ADSs") listed on The Nasdaq Capital Market. Each ADS represents a certain number of Shares. As announced on 25 July 2019, the Co |
|
| November 19, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November (Commission File Number 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) 14/114 William Street, Melbourne, VIC, 3000, Australia (Address of principa |
|
| October 31, 2019 |
ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report EX-99.1 2 bntc-ex9916.htm EX-99.1 Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report Highlights: • Cash reserves of approximately A$24.6 million • Secured A$3.22 million of additional funding through a Registered Direct Offering • BB-301 (OPMD) to be evaluated in three non-clinical studies to facilitate filing of the Investigational New Drug (IND) application and initiati |
|
| October 31, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K APPENDIX 4C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) 14/114 William Street, Melbourne, VIC, 3000, Australia (Address of principal executiv |
|
| October 31, 2019 |
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B EX-99.2 3 bntc-ex9927.htm EX-99.2 Exhibit 99.2 Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Name of entity BENITEC BIOPHARMA LIMITED ABN Quarter ended (“current quarter”) 64 068 943 662 30 September 2019 Consolidated statement of cash flows Current quarter $A’000 Year to date (3 months) $A’00 |
|
| October 30, 2019 |
Exhibit 12.2 Certification of the principal financial officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, Megan Boston, certify that: 1. I have reviewed this annual report on Form 20-F of Benitec Biopharma Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the stateme |
|
| October 30, 2019 |
BNTC / Benitec Biopharma Ltd 20-F - - 20-F 20-F 1 bntc-20f20190630.htm 20-F c UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20‑F (Mark one) ☐ Registration statement pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2019 or ☐ Transition report pursuant to Section 13 |
|
| October 30, 2019 |
Certification of principal executive officer pursuant to 18 U.S.C. Section 1350 Exhibit 13.1 Certification of the principal executive officer required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Dr. Jerel Banks, Chief Executive Officer of Benitec Bio |
|
| October 30, 2019 |
Certification of principal financial officer pursuant to 18 U.S.C. Section 1350 Exhibit 13.2 Certification of the principal financial officer required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Ms. Megan Boston, Executive Director and Head of Austra |
|
| October 30, 2019 |
Consent of Grant Thornton Audit Pty Ltd Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We have issued our report dated October 30, 2019, with respect to the consolidated financial statements included in the Annual Report of Benitec Biopharma Limited on Form 20-F for the year ended June 30, 2019. We consent to the incorporation by reference of said report in the Registration Statement of Benitec Biopharma Limited o |
|
| October 30, 2019 |
Exhibit 12.1 Certification of the principal executive officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, Jerel Banks, certify that: 1. I have reviewed this annual report on Form 20-F of Benitec Biopharma Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statemen |
|
| October 24, 2019 |
Rule 424(b)(3) File No. 333-196105 Note: This revised form of American Depositary Receipt is being filed to reflect that the ratio of Shares per American Depositary Share has changed from twenty shares to two hundred shares, effective November 18, 2019. EXHIBIT A AMERICAN DEPOSITARY SHARES (Each American Depositary Share represents Two Hundred (200) deposited Shares) THE BANK OF NEW YORK MELLON AM |
|
| October 7, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Benitec Biopharma Limited (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 082053307** (CUSIP Number) September 26, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whi |
|
| September 30, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Dated September 30, 2019 Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, William Street Melbourne 3000, VIC, Australia (Address of princi |
|
| September 30, 2019 |
EX-99.2 3 d812687dex992.htm EX-99.2 Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of September 30, 2019, is between Benitec Biopharma Limited, of Level 14, 114 William Street, Melbourne 3000, Victoria, Australia, an Australian public company incorporated under the laws of the Commonwealth of Australia (the “Company”), and each purchaser |
|
| September 30, 2019 |
PLACEMENT AGENCY AGREEMENT September 30, 2019 EX-99.1 2 d812687dex991.htm EX-99.1 Exhibit 99.1 PLACEMENT AGENCY AGREEMENT September 30, 2019 Ladenburg Thalmann & Co. Inc. 999 Vanderbilt Beach Road, Suite 200 Naples, Florida 34105 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Benitec Biopharma Limited, of Level 14, 114 William Street, Melbourne 3000, Victoria, Australia, an Australian public |
|
| September 30, 2019 |
Benitec Biopharma Limited Announces US$2.25 Million Registered Direct Offering EX-99.5 Exhibit 99.5 September 30, 2019 Benitec Biopharma Limited Announces US$2.25 Million Registered Direct Offering New York, USA and Melbourne, Australia, September 30, 2019: Benitec Biopharma Limited (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) (“Benitec” or the “Company”) today announces it has entered into a securities purchase agreement (“SPA”) with certain institutional, sophisticated and profess |
|
| September 30, 2019 |
EX-99.3 Exhibit 99.3 PRE-FUNDED AMERICAN DEPOSITARY SHARES PURCHASE WARRANT BENITEC BIOPHARMA LIMITED Warrant ADSs: Issue Date: THIS PRE-FUNDED AMERICAN DEPOSITARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| September 30, 2019 |
EX-99.4 Exhibit 99.4 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV |
|
| September 30, 2019 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-218400 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 5, 2017) Benitec Biopharma Limited Ordinary Shares represented by 2,800,000 American Depositary Shares Warrants to purchase 412,863 American Depositary Shares This prospectus supplement relates to the offer and sale of 56,000,000 ordinary shares of Benitec Biopharma Limite |
|
| September 24, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, William Street, Melbourne VIC 3000 AUSTRALIA (Address of registrant’s pri |
|
| September 24, 2019 |
Benitec Corporate Overview Ladenburg Thalmann September 2019 Exhibit 99.1 Benitec Biopharma: General Financial and Capital Markets Overview Benitec Biopharma: Gene therapy-focused biotechnology company developing novel genetic medicines derived from the proprietary DNA-directed RNA interference (“ddRNAi”) platform Market Cap: USD$8.6 million Net Cash (June 30, 2019): USD$15.5 million Public Listin |
|
| September 19, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K 6-K 1 bntc-6k20190919.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, William Street, Melbourne VIC 3000 AUSTRALI |
|
| September 19, 2019 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma to present at Ladenburg Thalmann 2019 Healthcare Conference MELBOURNE – September 19, 2019 – Benitec Biopharma Ltd (ASX: BLT, NASDAQ: BNTC), a gene therapy-focused biotechnology company developing novel genetic medicines derived from the proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced that Jerel A. Banks, M.D. Ph |
|
| September 16, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K 6-K 1 bntc-6k20190916.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AU |
|
| September 16, 2019 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma Provides Update on BB-301 Oculopharyngeal Muscular Dystrophy (OPMD) Program MELBOURNE – September 16, 2019 – Benitec Biopharma (ASX: BLT, NASDAQ: BNTC), a gene therapy-focused biotechnology company developing novel genetic medicines derived from the proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced their plans to c |
|
| August 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 30, 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, William Street, Melbourne VIC 3000 AUSTRALIA (Address of registrant’s prin |
|
| August 29, 2019 |
Exhibit 99.1 Appendix 4E - Preliminary Final Report year ended June 30, 2019 This information should be read in conjunction with Benitec’s Annual Report which is enclosed. 1. Company details Name of entity: Benitec Biopharma Limited ABN: 64 068 943 662 Reporting period: For the year ended June 30, 2019 Previous period: For the year ended June 30, 2018 2. Results for announcement to the market $'00 |
|
| August 29, 2019 |
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Exhibit 99.1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Rules 4.7.3 and 4.10.31 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Introduced 01/07/14 Amended 02/11/15 Name of entity Benitec Biopharma Limited ABN / ARBN Fiscal year ended: 64 068 943 662 30 June 2019 Our corporate governance statement2 for the a |
|
| August 29, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Level 14, William Street, Melbourne VIC 3000 AUSTRALIA (Address of registrant’s princi |
|
| August 29, 2019 |
2019 Corporate Governance Statement Exhibit 99.2 2019 Corporate Governance Statement This Corporate Governance Statement of Benitec Biopharma Limited (the Company) has been prepared in accordance with the 3rd Edition of the Australian Securities Exchange’s (ASX) Corporate Governance Principles and Recommendations of the ASX Corporate Governance Council (ASX Principles and Recommendations). The Company’s ASX Appendix 4G, which is a c |
|
| July 31, 2019 |
EX-99.1 2 bntc-ex99110.htm EX-99.1 Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report MELBOURNE – July 31, 2019 – Benitec Biopharma (ASX: BLT, NADSAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, |
|
| July 31, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of registrant’s pr |
|
| July 31, 2019 |
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B EX-99.2 3 bntc-ex9929.htm EX-99.2 Exhibit 99.2 Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Name of entity BENITEC BIOPHARMA LIMITED ABN Quarter ended (“current quarter”) 64 068 943 662 30 June 2019 Consolidated statement of cash flows Current quarter $A’000 Year to date (12 months) $A’000 1. |
|
| July 25, 2019 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Receives Notice from Nasdaq Sydney, 25 July 2019: Benitec Biopharma Limited ("Benitec" or the "Company") (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) has its ordinary shares listed on the Australian Securities Exchange and American Depositary Shares ("ADSs") listed on The Nasdaq Capital Market. Each ADS represents 20 ordinary shares of the Company. On 23 July 2 |
|
| July 25, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of registrant’s pr |
|
| July 23, 2019 |
Exhibit 99.1 23 July 2019 Lisa Banh Senior Adviser, Listings Compliance ASX Compliance Pty Ltd 20 Bridge Street Sydney NSW 2000 By e-mail: [email protected] [email protected] Dear Ms Banh ASX Query I refer to your letter dated 19 July 2019. Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC) (Benitec, or the Company) advises as follows in response to each of the queries: 1. The |
|
| July 23, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of registrant’s pr |
|
| June 6, 2019 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Update on Oculopharyngeal Muscular Dystrophy Program Sydney, Australia, 6 June 2019: Benitec Biopharma Limited (“Benitec” or the “Company”) (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced the termination of the License and Collaboration Agreement with Axovant Sciences, as the Benitec team endeavors to conduct several additional exploratory analyses prior |
|
| June 6, 2019 |
BNTC / Benitec Biopharma Ltd 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of registrant’s pr |
|
| April 24, 2019 |
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Exhibit 99.1 Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Name of entity BENITEC BIOPHARMA LIMITED ABN Quarter ended (“current quarter”) 64 068 943 662 31 March 2019 Consolidated statement of cash flows Current quarter $A’000 Year to date (6 months) $A’000 1. Cash flows from operating activit |
|
| April 24, 2019 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of registrant’s p |
|
| March 8, 2019 |
Appendix 3B New issue announcement, application for quotation of additional securities and agreement Exhibit 99.1 Rule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New issue announcement, application for quotation of additional securities and agreement Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09 |
|
| March 8, 2019 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of registrant’s p |
|
| February 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of registrant’ |
|
| February 26, 2019 |
Exhibit 99.1 BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 Appendix 4D Results for Announcement to the Market for the half-year ended December 31, 2018 The following information is provided under listing rule 4.2A 1. Reporting period The financial information contained in this report is for the half-year ended December 31, 2018. Comparative amounts for the Consolidated Statement of Profit or Loss a |
|
| February 14, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Benitec Biopharma Limited (Name of Issuer) Ordinary Shares (Title of Class of Securities) Q14711263 (CUSIP Number) December 31, 2018 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| January 31, 2019 |
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Exhibit 99.2 Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Name of entity BENITEC BIOPHARMA LIMITED ABN Quarter ended (“current quarter”) 64 068 943 662 31 December 2018 Consolidated statement of cash flows Current quarter $A’000 Year to date (6 months) $A’000 1. Cash flows from operating acti |
|
| January 31, 2019 |
EX-99.1 2 bntc-ex9918.htm EX-99.1 Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report SYDNEY January 31, 2019 – Benitec Biopharma (ASX: BLT, NADSAQ: BNTC) ("Benitec" or the "Company"), a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, to |
|
| January 31, 2019 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2019 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of registrant’s |
|
| December 21, 2018 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Provides Update on BB-401 Cancer Treatment Program SYDNEY, AUSTRALIA & HAYWARD, CA — December 21, 2018 — Benitec Biopharma (ASX: BLT, NADSAQ: BNTC) (the “Company”), a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, to |
|
| December 21, 2018 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2018 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of registrant’ |
|
| November 9, 2018 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2018 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of registrant’ |
|
| November 9, 2018 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Results of the Annual General Meeting Held on Thursday 8 November 2018 Sydney, Australia, 8 November 2018: In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), Benitec Biopharma Limited (“Benitec” or the “Company”) (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) advises details of the resolutions and the proxies received in respec |
|
| November 9, 2018 |
NASDAQ: BNTC | ASX: BLT PATHWAY TO VALUE CREATION Annual General Meeting Presentation 8 November 2018 Jerel A. |
|
| October 30, 2018 |
20-F 1 bntc-20f20180630.htm 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20‑F (Mark one) ☐ Registration statement pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2018 or ☐ Transition report pursuant to Section 13 o |
|
| October 30, 2018 |
Exhibit 4.14 EXECUTION COPY **** INDICATES CONFIDENTIAL MATERIAL OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION SEPARATELY WITH A REQUEST FOR CONFIDENTIAL TREATMENT LICENSE AND COLLABORATION AGREEMENT THIS LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is entered into as of July 9, 2018 (the “Effective Date”), by and between B |
|
| October 30, 2018 |
Exhibit 12.2 Certification of the principal financial officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, Megan Boston, certify that: 1. I have reviewed this annual report on Form 20-F of Benitec Biopharma Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the stateme |
|
| October 30, 2018 |
Certification of principal financial officer pursuant to 18 U.S.C. Section 1350 Exhibit 13.2 Certification of the principal financial officer required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Ms. Megan Boston, Executive Director and Head of Austra |
|
| October 30, 2018 |
Certification of principal executive officer pursuant to 18 U.S.C. Section 1350 Exhibit 13.1 Certification of the principal executive officer required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Dr. Jerel Banks, Chief Executive Officer of Benitec Bio |
|
| October 30, 2018 |
Exhibit 4.15 EXECUTION COPY **** INDICATES CONFIDENTIAL MATERIAL OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION SEPARATELY WITH A REQUEST FOR CONFIDENTIAL TREATMENT July 23, 2018 Jerel A Banks, M.D., Ph.D. Executive Chairman Benitec Biopharma Limited Suite 1201, 99 Mount Street North Sydney NSW 2060 Australia Re:Amendment No. 1 to Lic |
|
| October 30, 2018 |
Exhibit 12.1 Certification of the principal executive officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, Jerel Banks, certify that: 1. I have reviewed this annual report on Form 20-F of Benitec Biopharma Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statemen |
|
| October 29, 2018 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2018 (Commission File No. 001-37518) Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of registrant’s |
|
| October 29, 2018 |
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B EX-99.1 2 bntc-ex9916.htm EX-99.1 Exhibit 99.1 Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Name of entity BENITEC BIOPHARMA LIMITED ABN Quarter ended (“current quarter”) 64 068 943 662 30 September 2018 Consolidated statement of cash flows Current quarter $A’000 Year to date (3 months) $A’00 |
|
| October 9, 2018 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| October 9, 2018 |
BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 NOTICE OF 2018 ANNUAL GENERAL MEETING Exhibit 99.1 BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 NOTICE OF 2018 ANNUAL GENERAL MEETING Notice is hereby given that the 2018 Annual General Meeting of the Shareholders of Benitec Biopharma Limited (“the Company” or "Benitec") will be held at the offices of Grant Thornton, Level 17, 383 Kent Street, Sydney NSW 2000 on Thursday, 8 November 2018 at 10.00am AEDT. Further details in respect of |
|
| September 21, 2018 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of pri |
|
| September 21, 2018 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma Announces the Appointment of Gregory R. Reyes, M.D., Ph.D. as Senior Scientific Advisor Sydney, Australia,19 September 2018: Benitec Biopharma Limited (“Benitec” or the “Company”) (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference ( |
|
| September 4, 2018 |
Exhibit 99.1 BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 Appendix 4E – Preliminary Final Report year ended June 30, 2018 This information should be read in conjunction with Benitec’s Annual Report which is enclosed. Reporting period: For the year ended June 30, 2018 Previous period: For the year ended June 30, 2017 Results for Announcement to the Market Change %Change $A'000 Revenue from ordinary |
|
| September 4, 2018 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princi |
|
| August 1, 2018 |
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Exhibit 99.1 Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Name of entity BENITEC BIOPHARMA LIMITED ABN Quarter ended (“current quarter”) 64 068 943 662 30 June 2018 Consolidated statement of cash flows Current quarter $A’000 Year to date (12 months) $A’000 1. Cash flows from operating activit |
|
| August 1, 2018 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principa |
|
| July 9, 2018 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Announces Global Licensing Agreement for BB-301 for Treatment of Oculopharyngeal Muscular Dystrophy and Broad Platform Collaboration with Axovant · Benitec to receive upfront cash payment of US$10 million with additional cash payments totalling US$17.5 million (a total of US$27.5M) upon completion of near-term milestones for BB-301, now named AXO-AAV-OP |
|
| July 9, 2018 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principa |
|
| June 29, 2018 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec announces Change of Company Secretary Sydney, Australia, 29 June 2018: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (“Benitec” or “the Company”), has today appointed Mr Oliver Kidd as its Company Secretary, effective immediately. Mr Kidd has a legal background, having also acted as Company Secretary for a number ASX-listed organisati |
|
| June 29, 2018 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principa |
|
| June 15, 2018 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec announces organisational restructure Sydney, Australia, 15 June 2018: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (Benitec or the Company) As Benitec progresses its major assets toward clinical validation the Company announces that it has made strategic changes to its Board and management as part of an organisational restructure. T |
|
| June 15, 2018 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principa |
|
| June 4, 2018 |
Consolidated Nine months ended Exhibit 99.1 BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 Interim Report for the nine months ended March 31, 2018 1. Reporting period The financial information contained in this report is for the nine months ended March 31, 2018. Comparative amounts for the Consolidated Statement of Profit or Loss and Other Comprehensive Income are for the nine months ended March 31, 2017. Financial Position compa |
|
| June 4, 2018 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principal |
|
| May 31, 2018 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma reports financial results for the 2018 fiscal third quarter and provides operational update Sydney, Australia, 31 May 2018: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (“Benitec” or “the Company”), a biotechnology company developing innovative therapeutics based on a combination of gene therapy with its patented gene-sile |
|
| May 31, 2018 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) 6-K 1 tv4955306k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 A |
|
| May 31, 2018 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principal |
|
| May 31, 2018 |
Exhibit 99.1 ASX ANNOUNCEMENT Entitlement offer results and notification of under-subscriptions Not for release to US newswire services in the United States Sydney, Australia, 31 May 2018: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (Benitec or the Company) confirms that the Company's previously announced 1 for 2 pro rata renounceable entitlement offer of fully paid ordinary s |
|
| May 24, 2018 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma receives Russian Regulatory Approval for Oncology Study Sydney, Australia, 24 May 2018: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (“Benitec” or “the Company”), a biotechnology company developing innovative therapeutics based on a combination of gene therapy and its patented gene-silencing technology named ddRNAi or ‘expr |
|
| May 24, 2018 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principal |
|
| May 9, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Benitec Biopharma Limited (Name of Issuer) Ordinary Shares (Title of Class of Securities) 082053307** (CUSIP Number) April 30, 2018 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedule 1 |
|
| May 3, 2018 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec to Host Investor Webinar on the Company’s Oculopharyngeal Muscular Dystrophy (OPMD) Program - Details on the Company’s OPMD program and roadmap to be presented by Benitec Management Team - Discussion on disease and market to be presented by internationally renowned key opinion leader Bernard Brais from the Montreal Neurological Institute Sydney, Austral |
|
| May 3, 2018 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principal |
|
| May 1, 2018 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principal executive office |
|
| May 1, 2018 |
URGENT Acceptance Due 5:00 pm (New York time) on 27 April 2018 EX-99.1 Exhibit 99.1 Private and Confidential 27 April 2018 Highbridge Capital Management, LLC 40 West 57th Street 32nd Floor New York, NY 10019 Attn: Paul Mann URGENT Acceptance Due 5:00 pm (New York time) on 27 April 2018 Dear Paul, Subscription of American Depositary Shares 1. Introduction Benitec Biopharma Limited, an Australian corporation (ACN 068 943 662) (Benitec or the Company), is offeri |
|
| May 1, 2018 |
Benitec Biopharma Limited 772,201 American Depositary Shares Representing 15,444,020 Ordinary Shares 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-218400 PROSPECTUS SUPPLEMENT (To Prospectus dated July 5, 2017) Benitec Biopharma Limited 772,201 American Depositary Shares Representing 15,444,020 Ordinary Shares This prospectus supplement relates to the offer and sale of 772,201 American Depositary Shares, or ADSs. Each ADS represents 20 ordinary shares in Benitec Bi |
|
| April 30, 2018 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princip |
|
| April 30, 2018 |
Exhibit 99.1 ASX ANNOUNCEMENT Benitec announces an institutional share placement and a 1 for 2 renounceable entitlement offer · Placement to leading global institutional investor · 1 for 2 pro rata renounceable entitlement offer to eligible shareholders at AUD 17 cents, a 19% discount to the latest closing price · Major shareholder, Nant Capital LLC, and the Benitec Directors intend on taking up t |
|
| April 24, 2018 |
BB-401-01: Phase 2 Clinical Study in HNSCC Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT HNSCC and OPMD program update Sydney, Australia, 24 April 2018: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today provided an update on its two lead programs in head and neck squamous cell carcinoma (HNSCC) and oculopharyngeal muscular dystrophy (OPMD). This update should be read in conjunction with the latest corporate presentation which |
|
| April 24, 2018 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princip |
|
| February 22, 2018 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update Sydney, Australia, 22 February 2018: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (?Benitec? or ?the Company?), a biotechnology company developing innovative therapeutics based on a combination of gene therapy with its patented gene |
|
| February 22, 2018 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| February 22, 2018 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| February 22, 2018 |
Exhibit 99.1 BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 Appendix 4D Results for Announcement to the Market for the half-year ended December 31, 2017 The following information is provided under listing rule 4.2A 1. Reporting period The financial information contained in this report is for the half-year ended December 31, 2017. Comparative amounts for the Consolidated Statement of Profit or Loss a |
|
| January 30, 2018 |
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Exhibit 99.1 Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Name of entity BENITEC BIOPHARMA LIMITED ABN Quarter ended (?current quarter?) 64 068 943 662 31 December 2017 Consolidated statement of cash flows Current quarter $A?000 Year to date (6 months) $A?000 1. Cash flows from operating acti |
|
| January 30, 2018 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| January 23, 2018 |
Exhibit 99.1 ASX ANNOUNCEMENT Federal R&D Tax Credit Received Sydney Australia, 23 January 2018: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) advises that it has received a $4,112,058 cash refund for the year ended 2017 under the Federal Government?s R&D Tax Incentive Scheme. The refund relates to the costs of research and development which qualify as eligible R&D expenditure |
|
| January 23, 2018 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| January 17, 2018 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec receives U.S. Orphan Drug Designation for BB-301, its ddRNAi therapeutic for the treatment of oculopharyngeal muscular dystrophy Sydney, Australia, 15 January 2018: Benitec Biopharma Limited (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) today announced that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to BB-301 for the treatment |
|
| January 17, 2018 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| December 8, 2017 |
BNTC / Benitec Biopharma Ltd POS AM POS AM Table of Contents As filed with the Securities and Exchange Commission on December 8, 2017. |
|
| November 29, 2017 |
Exhibit 99.1 BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 Interim Report for the three months ended September 30, 2017 1. Reporting period The financial information contained in this report is for the three months ended September 30, 2017. Comparative amounts for the Consolidated Statement of Profit or Loss and Other Comprehensive Income are for the three months ended September 30, 2016. Financial |
|
| November 29, 2017 |
BNTC / Benitec Biopharma Ltd 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| November 29, 2017 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| November 29, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma reports financial results for the 2018 fiscal first quarter and provides operational update Sydney, Australia, 29 November 2017: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (?Benitec? or ?the Company?), a biotechnology company developing innovative therapeutics based on a combination of gene therapy with its patented gene- |
|
| November 29, 2017 |
BNTC / Benitec Biopharma Ltd FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| November 29, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma provides update on OPMD orphan disease program · Orphan application submitted with the U.S. Food & Drug Administration · Pre-IND and scientific advice meetings completed with regulatory agencies · On track to advance into human clinical trials by the end of calendar year 2018 Sydney, Australia, 27 November 2017: Benitec Biopharma Limited (ASX: |
|
| October 31, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| October 31, 2017 |
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Exhibit 99.1 Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Name of entity BENITEC BIOPHARMA LIMITED ABN Quarter ended (“current quarter”) 64 068 943 662 30 September 2017 Consolidated statement of cash flows Current quarter $A’000 Year to date (3 months) $A’000 1. Cash flows from operating act |
|
| October 23, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| October 23, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec announces resignation of Director, Dr John Chiplin Sydney, Australia, 23 October 2017: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) announces that Dr John Chiplin, who served on the Benitec Biopharma Limited Board since 2010, has resigned as a Non-Executive Director, effective immediately. Benitec Chairman, Dr Jerel Banks said: “John |
|
| October 23, 2017 |
20-F 1 d434585d20f.htm FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark one) ☐ Registration statement pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2017 or ☐ Transition report pursua |
|
| October 12, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| October 12, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec announces the appointment of a new Chairman Sydney, Australia, 12 October 2017: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce the appointment of Dr. Jerel Banks to Chairman of the Board, replacing Mr. Peter Francis who will remain on the Board as a non-executive Director. Dr. Banks first joined the Board of Beni |
|
| October 11, 2017 |
Exhibit 99.1 BENITEC BIOPHARMA LIMITED Annual Report 2017 Contents Directors Report 1 Corporate governance 26 Auditor’s independence declaration 27 Statement of profit or loss and other comprehensive income 28 Statement of financial position 29 Statement of changes in equity 30 Statement of cash flow 31 Notes to the financial statements 32 Directors’ declaration 57 Independent auditor’s report to |
|
| October 11, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| October 11, 2017 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| October 11, 2017 |
Exhibit 99.1 ASX ANNOUNCEMENT Benitec announces resignation of Chief Business and Operations Officer Sydney, Australia, 10 October 2017: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) informs the markets that Cliff Holloway has today resigned from his position as Chief Business and Operations Officer, effective early January 2018, in order to pursue other interests overseas. Clif |
|
| October 10, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| October 10, 2017 |
BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 NOTICE OF 2017 ANNUAL GENERAL MEETING EX-99.1 2 v476639ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 NOTICE OF 2017 ANNUAL GENERAL MEETING Notice is hereby given that the 2017 Annual General Meeting of the shareholders of Benitec Biopharma Limited (“the Company” or "Benitec") will be held at the offices of Grant Thornton Australia, Level 17, 383 Kent Street Sydney on 8 November 2017 at 10.00am AEDT. |
|
| August 29, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princi |
|
| August 29, 2017 |
EX-99.1 2 v474248ex99-1.htm EX-99.1 Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma reports fiscal full year 2017 financial results and provides operational update Sydney, Australia, 29 August 2017: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (“Benitec” or “the Company”), a biotechnology company developing innovative therapeutics based on its patented gene-silencing tec |
|
| August 29, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princi |
|
| August 29, 2017 |
Exhibit 99.1 Appendix 4E Final year ended 30 June 2017 This information should be read in conjunction with Benitec?s Annual Report which is enclosed. 1. Company details Name of entity: Benitec Biopharma Limited ABN: 64 068 943 662 Reporting period: For the year ended 30 June 2017 Previous period: For the year ended 30 June 2016 2. Results for announcement to the market $'000 Revenues from ordinary |
|
| August 23, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma announces participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017 Sydney, Australia, 23 August 2017: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Con |
|
| August 23, 2017 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4738866k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 |
|
| August 8, 2017 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princi |
|
| August 8, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma advances OPMD orphan disease program · Innovative vector design to ‘silence and replace’ the disease-causing gene in a single construct · Single vector performance matches excellent outcomes seen in the dual vector system as reported in Nature Communications in April 2017 · On track to advance into human clinical trials in the second half of c |
|
| July 31, 2017 |
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Exhibit 99.1 Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Name of entity BENITEC BIOPHARMA LIMITED ABN Quarter ended (?current quarter?) 64 068 943 662 30 June 2017 Consolidated statement of cash flows Current quarter $A?000 Year to date (12 months) $A?000 1. Cash flows from operating activit |
|
| July 31, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principa |
|
| July 31, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principa |
|
| July 31, 2017 |
Appendix 3B New issue announcement, application for quotation of additional securities and agreement Exhibit 99.1 Rule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New issue announcement, application for quotation of additional securities and agreement Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX?s property and may be made public. Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09 |
|
| June 30, 2017 |
CORRESP Benitec Biopharma Limited 99 Mount Street, Suite 1201 North Sydney, NSW 2060 Australia June 30, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100F Street, N. |
|
| June 9, 2017 |
Exhibit 99.1 ASX ANNOUNCEMENT Federal R&D Tax Credit Received Sydney Australia, 9 June 2017: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) advises that it has received an additional $636,056 cash refund for the year ended 2016 under the Federal Government’s R&D Tax Incentive Scheme. The refund relates to the costs of research and development which qualify as eligible R&D expend |
|
| June 9, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principa |
|
| June 2, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT US Securities and Exchange Commission (?SEC?) Shelf Registration Statement filed Sydney Australia, 2 June 2017: Benitec Biopharma Limited (the ?Company?) (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that it has filed a Shelf Registration Statement on Form F-3 with the US Securities and Exchange Commission (the ?SEC?). When declared effective by the S |
|
| June 2, 2017 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principa |
|
| June 1, 2017 |
F-3 Table of Contents As filed with the Securities and Exchange Commission on June 1, 2017. |
|
| June 1, 2017 |
EX-10.1 3 d406425dex101.htm EX-10.1 Exhibit 10.1 BENITEC BIOPHARMA LIMITED SHARE SUBSCRIPTION AGREEMENT THIS SHARE SUBSCRIPTION AGREEMENT (the “Agreement”) is made and entered into as of October 24, 2016 by and among BENITEC BIOPHARMA LIMITED, an Australian corporation (“Company”), and Nant Capital, LLC, a Delaware limited liability company (the “Purchaser”). RECITALS WHEREAS, the Company desires |
|
| June 1, 2017 |
EX-10.2 Exhibit 10.2 **** INDICATES CONFIDENTIAL MATERIAL OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION SEPARATELY WITH A REQUEST FOR CONFIDENTIAL TREATMENT. EXECUTION COPY EXCLUSIVE SUBLICENSE AGREEMENT This Exclusive Sublicense Agreement (this ?Agreement?) is made and entered into as of the 23rd day of December, 2016 (?Effective Da |
|
| June 1, 2017 |
EX-10.3 5 d406425dex103.htm EX-10.3 Exhibit 10.3 RESEARCH COLLABORATION AGREEMENT This RESEARCH COLLABORATION AGREEMENT (including the exhibits hereto, this “Agreement”) is made as of January 27, 2017 (the “Effective Date”) by and between Benitec Biopharma Limited, an Australian corporation (“Benitec”), and Nant Capital, LLC, a Delaware limited liability company (“Nant”). Nant and Benitec are each |
|
| May 30, 2017 |
Exhibit 99.1 BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 Interim Report for the nine months ended March 31, 2017 1. Reporting period The financial information contained in this report is for the nine months ended March 31, 2017. Comparative amounts for the Consolidated Statement of Profit or Loss and Other Comprehensive Income are for the nine months ended March 31, 2016. Financial Position compa |
|
| May 30, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of principal |
|
| April 4, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Key pre-clinical data on oculopharyngeal muscular dystrophy (OPMD) published in Nature Communications Sydney, Australia, 3 April 2017: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that the initial pre-clinical efficacy results of the OPMD program have been published in Nature Communications, an open access scientific j |
|
| April 4, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princip |
|
| March 24, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princip |
|
| March 24, 2017 |
Exhibit 99.1 ASX ANNOUNCEMENT Federal R&D Tax Credit Received Sydney Australia, 24 March 2017: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) advises that it has received a $5,590,235 cash refund under the Federal Government?s R&D Tax Incentive Scheme. The refund relates to the costs of research and development which qualify as eligible R&D expenditure under the Federal Governmen |
|
| March 15, 2017 |
BNTC / Benitec Biopharma Ltd / CALIFORNIA CAPITAL EQUITY, LLC - SC 13D/A Activist Investment SC 13D/A 1 d303376dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Under the Securities Exchange Act of 1934 Benitec Biopharma Limited (Name of Issuer) Ordinary Shares (Title of Cl |
|
| March 13, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princip |
|
| March 13, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma completes second tranche placement to Nant Capital to raise A$5.45 million · Second tranche placement of 29,305,819 shares to Nant Capital · Funds raised will be used to support the scientific collaboration between Benitec and NantWorks, and for Benitec’s existing programs Sydney, Australia, 13 March 2017: Benitec Biopharma Limited (ASX:BLT; N |
|
| March 3, 2017 |
Benitec Biopharma SC 13D/A (Activist Acquisition of More Than 5% of Shares) SC 13D/A 1 d354469dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Benitec Biopharma Limited (Name of Issuer) Ordinary Shares (Title of Class of Securities) 082053307 (CUSIP Number) California Capital Equity, LLC Attn: Patrick Soon-Shiong 9922 Jefferson Boulevard C |
|
| February 23, 2017 |
Exhibit 99.1 BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 Appendix 4D Results for Announcement to the Market for the half year ended December 31, 2016 The following information is provided under listing rule 4.2A 1. Reporting period The financial information contained in this report is for the half-year ended December 31, 2016. Comparative amounts for the Consolidated Statement of Profit or Loss a |
|
| February 23, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| February 17, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma to present expanded data set from pivotal data in hepatitis B virus (HBV) in vivo model at International Liver Meeting in Shanghai, China · Demonstrates that a single administration of ddRNAi agent can significantly improve HBV suppression in combination with existing anti-HBV therapies · Informs clinical development path and defines the poten |
|
| February 17, 2017 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| February 6, 2017 |
Exhibit 99.1 ASX ANNOUNCEMENT Amendment to investment dates under Nant Share Subscription Agreement Sydney Australia, 3 February 2017: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) and Nant Capital LLC have executed an amendment to the Share Subscription Agreement to revise the dates by which the second tranche of equity investment by Nant Capital and the broader placement of ad |
|
| February 6, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| February 3, 2017 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| February 3, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma makes significant progress in ocular program · Data to be presented at industry leading conferences · Development of novel viral vectors for delivery to the back of the eye · Expanded potential of developing ddRNAi technology into ocular indications Sydney, Australia, 2 February 2017: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: B |
|
| January 31, 2017 |
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Exhibit 99.1 Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Name of entity BENITEC BIOPHARMA LIMITED ABN Quarter ended (?current quarter?) 64 068 943 662 31 December 2016 Consolidated statement of cash flows Current quarter $A?000 Year to date ( 6 months) $A?000 1. Cash flows from operating act |
|
| January 31, 2017 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| January 30, 2017 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| January 30, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec initiates development work on head and neck cancer programs after executing Collaboration Agreement with Nant Capital ? Builds inherent value into company by in licensing asset ready for mid-stage clinical testing ? Aims to commence a Phase II clinical study with in licensed antisense-EGFR asset by early 2018 ? Follow-on anti-EGFR ddRNAi program extends |
|
| January 17, 2017 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of princ |
|
| January 17, 2017 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular Dystrophy Sydney, Australia, 17 January 2017: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that the European Commission, based on a favourable recommendation from |
|
| December 22, 2016 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| December 22, 2016 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec in-licenses clinical program for head and neck cancer from NantWorks · Returns Benitec to clinical stage company · Clinical proof of concept achieved via demonstration of durable anti-tumor activity in advanced head and neck cancer patients · Continued development under planned research collaboration with NantWorks Sydney, Australia, 23 December 2016: B |
|
| December 22, 2016 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Market Update Sydney, Australia, 22 December 2016: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) has today provided a market update on key upcoming events and recent changes to our clinical advisory boards. Nant strategic engagement On 24 October 2016 Benitec announced the initiation of a strategic engagement with Nant on an oncology-focused |
|
| December 22, 2016 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| December 20, 2016 |
Log Reduction of Serum HBV DNA Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec releases pivotal data in an in vivo hepatitis B model · Significant and sustained drop of serum HBV DNA levels, HBsAg levels and HBeAg levels with BB-103 and BB-102 in combination with current standard of care agents · Supports continued progression of lead product candidate towards the clinic Sydney, Australia, 20 December 2016: Benitec Biopharma Limit |
|
| December 20, 2016 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| November 23, 2016 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| November 23, 2016 |
EX-99.1 2 v453717ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Interim Report for the Three Months Ended 30 September, 2016 Sydney, Australia – 22 November, 2016 - Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its Interim Report for the three months ended 30 September, 2016. The report includes the financial results and a review of operations for the |
|
| November 18, 2016 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| November 18, 2016 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma to Host Corporate Update Conference Call Conference Call and Live Audio Webcast Scheduled for Wednesday, 23 November 2016 at 8:00am AEDT / Tuesday, 22 November at 4:00pm EST Sydney Australia, 18 November 2016: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that the Company will host a conference call and live |
|
| November 16, 2016 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| November 16, 2016 |
Exhibit 99.1 General information The financial statements cover Benitec Biopharma Limited as a Group consisting of Benitec Biopharma Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Benitec Biopharma Limited's functional and presentation currency. Benitec Biopharma Limited is a listed public company li |
|
| November 15, 2016 |
BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 NOTICE OF 2016 ANNUAL GENERAL MEETING EX-99.1 2 v453147ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BENITEC BIOPHARMA LIMITED ABN 64 068 943 662 NOTICE OF 2016 ANNUAL GENERAL MEETING Notice is hereby given that the 2016 Annual General Meeting of the shareholders of Benitec Biopharma Limited (“the Company” or "Benitec") will be held at the offices of Grant Thornton Australia, Level 17, 383 Kent Street Sydney on 14 December 2016 at 10.00am AEDS |
|
| November 15, 2016 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant?s name into English) Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA (Address of prin |
|
| November 15, 2016 |
POS AM Table of Contents As filed with the Securities and Exchange Commission on November 15, 2016. |
|
| November 1, 2016 |
BNTC / Benitec Biopharma Ltd / CALIFORNIA CAPITAL EQUITY, LLC - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Under the Securities Exchange Act of 1934 Benitec Biopharma Limited (Name of Issuer) Ordinary Shares (Title of Class of Securities) 082053307 (CUSIP Number) Califo |
|
| November 1, 2016 |
EX-99.2 Exhibit 2 BENITEC BIOPHA RMA LIMITED ABN 64 068 943 662 Share Subscription Agreement October 24, 2016 BENITEC BIOPHA RMA LIMITED SHARE SUBSCRIPTION AGREEMENT THIS SHARE SUBSCRIPTION AGREEMENT (the “Agreement”) is made and entered into as of October 24, 2016 by and among BENITEC BIOPHARMA LIMITED, an Australian corporation (“Company”), and Nant Capital, LLC, a Delaware limited liability com |
|
| November 1, 2016 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Schedule 13D (including any and all amendments thereto) with respect to the Ordinary Shares of Benitec Biopharma Limited, and further agree that this Joint Filing Agreement shall be i |
|
| October 28, 2016 |
Form 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark one) ? Registration statement pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 or ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year ended June 30, 2016 or ? Transition report pursuant to Section 13 or 15(d) of the Securiti |
|
| October 24, 2016 |
Exhibit 99.1 ASX/NASDAQ ANNOUNCEMENT Benitec initiates a strategic engagement with NantVentures ? An oncology-focused research and development collaboration is planned that will return Benitec to the clinic with a Phase II gene-silencing asset that has achieved proof of concept in a solid tumour-based indication ? Chief Investment Officer of NantVentures, Jerel A. Banks, M.D., Ph.D. will be appoin |
|
| October 24, 2016 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) F6A, 1-15 Barr Street Balmain, NSW 2041 Australia (Address of principal execut |
|
| October 24, 2016 |
Exhibit 99.1 ASX ANNOUNCEMENT Benitec announces date of 2016 Annual General Meeting Sydney, Australia, 24 October 2016: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (?Benitec?) wishes to advise that ASIC has granted it an extension of time in which to hold its 2016 Annual General Meeting. The basis for the extension of time in which Benitec is to hold its 2016 Annual General Me |
|
| October 24, 2016 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) F6A, 1-15 Barr Street Balmain, NSW 2041 Australia (Address of principal execut |
|
| October 19, 2016 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) F6A, 1-15 Barr Street Balmain, NSW 2041 Australia (Address of principal execut |
|
| October 19, 2016 |
EX-99.1 2 v450757ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT Change in Company Secretary Sydney, Australia, 18 October 2016: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) wishes to advise the market that Ms Sakura Holloway who was appointed Joint Company Secretary on the 23 August 2016, left the Company on 11 October 2016. Mr Greg West remains as the Company Secretary. |
|
| October 7, 2016 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) F6A, 1-15 Barr Street Balmain, NSW 2041 Australia (Address of principal execut |
|
| October 7, 2016 |
Exhibit 99.1 NASDAQ ANNOUNCEMENT Benitec receives notification from NASDAQ in connection with an independent director’s resignation Sydney, Australia, 07 October 2016: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) announces that, pursuant to the rules of The NASDAQ Stock Market LLC (“NASDAQ”), the Company notified NASDAQ on 30 September 2016, that as a result of the previously-a |
|
| September 16, 2016 |
Exhibit 99.1 ASX ANNOUNCEMENT Benitec announces results from Phase I/IIa clinical study of TT-034 ? Primary study endpoint of safety met ? Transduction of hepatic tissue seen but no reduction in viral load ? Valuable learnings from this study incorporated into other programs Sydney, Australia, 16 September 2016: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) announces that its ph |
|
| September 16, 2016 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) F6A, 1-15 Barr Street Balmain, NSW 2041 Australia (Address of principal exec |
|
| August 30, 2016 |
Exhibit 99.1 Benitec Biopharma Limited Appendix 4E Preliminary final report 1. Company details Name of entity: Benitec Biopharma Limited ABN: 64 068 943 662 Reporting period: For the year ended 30 June 2016 Previous period: For the year ended 30 June 2015 2. Results for announcement to the market $'000 Revenues from ordinary activities down 57.1 % to 464 Loss from ordinary activities after tax att |
|
| August 30, 2016 |
Benitec Biopharma FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) F6A, 1-15 Barr Street Balmain, NSW 2041 Australia (Address of principal executi |
|
| August 16, 2016 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) F6A, 1-15 Barr Street Balmain, NSW 2041 Australia (Address of principal executi |
|
| August 16, 2016 |
Benitec Biopharma 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August Commission File Number 001-37518 Benitec Biopharma Limited (Translation of registrant’s name into English) F6A, 1-15 Barr Street Balmain, NSW 2041 Australia (Address of principal executi |
|
| August 16, 2016 |
EX-99.1 2 v447099ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT Benitec announces appointment of new Director and Chair of Audit Committee and retirement of Director, Mr Iain Ross Sydney, Australia, 16 August 2016: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) announces the appointment of Ms Megan Boston as Director of the Company and Chair of the Audit Committee, effecti |
|
| August 16, 2016 |
EX-99.1 2 v447099ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT Benitec announces appointment of new Director and Chair of Audit Committee and retirement of Director, Mr Iain Ross Sydney, Australia, 16 August 2016: Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) announces the appointment of Ms Megan Boston as Director of the Company and Chair of the Audit Committee, effecti |
